Search results
Results from the WOW.Com Content Network
In February 2010, a pneumococcal conjugate vaccine that protects against an additional six serotypes was introduced (PCV 13/brand name: Prevnar 13) and can be given instead of the original Prevnar. [27] [28] In June 2021, a pneumococcal conjugate vaccine which protects against 20 serotypes was approved with the brand name Prevnar 20. [29]
Prevnar vaccine. Prevnar 20 (PCV20) is the third version of a vaccine produced by the Wyeth subsidiary of Pfizer.In April 2023, the FDA approved Prevnar 20 for the prevention of invasive disease caused by the 20 different serotypes of S. pneumoniae contained in the vaccine (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) for individuals 6 ...
Pneumococcal polysaccharide vaccine, sold under the brand name Pneumovax 23, is a pneumococcal vaccine that is used for the prevention of pneumococcal disease caused by the 23 serotypes of Streptococcus pneumoniae contained in the vaccine as capsular polysaccharides. [2] It is given by intramuscular or subcutaneous injection. [2]
Merck's vaccine, branded Capvaxive, helped produce an immune response against all 21 serotypes, or variations of the bacteria, that the shot targeted in a variety of adult populations across studies.
2003 – First vaccine for Argentine hemorrhagic fever. [16] 2006 – First vaccine for human papillomavirus (which is a cause of cervical cancer) 2006 – First herpes zoster vaccine for shingles; 2011 – First vaccine for non-small-cell lung carcinoma (comprises 85% of lung cancer cases) 2012 – First vaccine for hepatitis E [17]
The vaccine, which older adults need only once, protects against pneumococcus bacteria, the leading cause of pneumonia in older adults, said Dr. Jiansheng Zhao, an internal medicine doctor in the ...
CORRECTION: (Oct. 24, 2024, 3:34 p.m. ET) Because of an editing error, a previous version of this article misstated the recommended dose for the pneumonia vaccine. It is intended as a single dose ...
This vaccine is a 2 or 3 dose series, depending on the brand of the vaccine, that is given at 2 and 4 months in the 2 dose series and at 2,4 and 6 months in the 3 dose series. Studies show that this vaccine is 85-98% effective against severe rotavirus disease and is 74-87% effective against rotavirus disease of any severity in the first year ...